Compugen Ltd. (NASDAQ:CGEN) Short Interest Update

Compugen Ltd. (NASDAQ:CGEN) was the recipient of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 1,630,000 shares, a drop of 5.8% from the August 15th total of 1,730,000 shares. Based on an average daily volume of 266,200 shares, the short-interest ratio is presently 6.1 days.

Hedge Funds Weigh In On Compugen

Several hedge funds have recently bought and sold shares of the stock. Heron Bay Capital Management acquired a new position in Compugen in the 1st quarter valued at about $32,000. Secure Asset Management LLC purchased a new position in shares of Compugen during the second quarter valued at approximately $69,000. Squarepoint Ops LLC lifted its stake in shares of Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 16,253 shares during the period. Rothschild Investment LLC acquired a new stake in shares of Compugen during the second quarter worth $380,000. Finally, ARK Investment Management LLC grew its position in shares of Compugen by 4.7% in the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after purchasing an additional 48,979 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Stock Performance

Compugen stock opened at $1.90 on Thursday. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The firm has a market capitalization of $169.56 million, a price-to-earnings ratio of -10.00 and a beta of 2.65. The stock’s fifty day moving average is $1.85 and its two-hundred day moving average is $2.07.

Compugen (NASDAQ:CGEN) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.06. The business had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.68 million. During the same quarter in the previous year, the firm posted ($0.11) EPS. As a group, sell-side analysts forecast that Compugen will post 0.07 EPS for the current fiscal year.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.